Unscrambling the Role of Redox-Active Biometals in Dopaminergic Neuronal Death and Promising Metal Chelation-Based Therapy for Parkinson's Disease.
Alfredo Gonzalez-AlcocerAna Patricia Duarte-JuradoAdolfo Soto-DominguezMaria de Jesus Loera-AriasEliud Enrique Villarreal-SilvaOdila Saucedo-CardenasRoberto Montes de Oca-LunaAracely Garcia-GarciaHumberto Rodríguez-RochaPublished in: International journal of molecular sciences (2023)
Biometals are all metal ions that are essential for all living organisms. About 40% of all enzymes with known structures require biometals to function correctly. The main target of damage by biometals is the central nervous system (CNS). Biometal dysregulation (metal deficiency or overload) is related to pathological processes. Chronic occupational and environmental exposure to biometals, including iron and copper, is related to an increased risk of developing Parkinson's disease (PD). Indeed, biometals have been shown to induce a dopaminergic neuronal loss in the substantia nigra. Although the etiology of PD is still unknown, oxidative stress dysregulation, mitochondrial dysfunction, and inhibition of both the ubiquitin-proteasome system (UPS) and autophagy are related to dopaminergic neuronal death. Herein, we addressed the involvement of redox-active biometals, iron, and copper, as oxidative stress and neuronal death inducers, as well as the current metal chelation-based therapy in PD.
Keyphrases
- oxidative stress
- cerebral ischemia
- dna damage
- signaling pathway
- diabetic rats
- ischemia reperfusion injury
- cell death
- induced apoptosis
- small molecule
- endoplasmic reticulum stress
- high resolution
- drug induced
- stem cells
- quantum dots
- risk assessment
- climate change
- cerebrospinal fluid
- electron transfer
- oxide nanoparticles